Pharma giant Merck expects Trump's tariffs to cost the company $200 million

Pharma giant Merck expects Trump's tariffs to cost the company $200 million

Merck is following Johnson & Johnson’s lead and reporting an expected financial hit from tariffs imposed by the Trump administration. In an April 24 earnings call, executives said they expect $200 million in tariff-related costs in 2025. Merck lowered its full-year profit expectations from $8.88–$9.03 per share to $8.82–$8.97 per share. The news comes a week after J&J executives said they expect $400 million in tariff-induced expenses in 2025. R…

Merck says it will eat $200 million in tariff costs

That figure does not account for the pharmaceutical tariffs the Trump administration is still weighing....

Merck shares fall after company lowers outlook on tariff impact

Shares of drug maker Merck & Co. declined Thursday after the company lowered its full-year profit guidance and said tariffs would add on $200 million in costs this year. Sales of its blockbuster cancer drug Keytruda failed to beat expectations and sales of the vaccine Gardasil declined in the quarter. The stock dropped 1.24% to $77.76 as of 10:27 a.m. after rising in premarket trading before the report. The drugmaker lowered its adjusted earning…